Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02177890
Other study ID # 1-Farmer
Secondary ID
Status Completed
Phase N/A
First received June 24, 2014
Last updated November 30, 2015
Start date November 2014
Est. completion date November 2015

Study information

Verified date November 2015
Source Wingate Institute of Neurogastroenterology
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

Nausea is a common and distressing experience that often precedes vomiting. Amongst symptoms emanating from the gastrointestinal (GI) tract nausea can be considered somewhat unique, as on one hand it represents a normal, highly conserved, physiological response to an ingested toxin yet on the other it may indicate pathology. Nausea may also arise as a consequence of pharmaco- and chemotherapeutic interventions. Nausea negatively impacts on quality of life, adherence to treatment and is a cause for discontinuation of the development of novel compounds. Experimentally, nausea can be induced in humans using a visually induced motion stimulus. Previously we have developed a 10-minute motion video of the landscape rotating as seen from the perspective of a subject standing on Westminster Bridge, London. The tilted and rotating view visual display makes the subject perceive that they are spinning round and round on a spot tilted away from centre of gravity due to circular vection. This motion video induced nausea in approximately 50% of healthy participants and caused a reduction in cardiac vagal tone, a validated measure of the parasympathetic nervous system branch on the autonomic nervous system. We therefore are evaluating the role of external transcutaneous vagal nerve stimulation in visually induced motion sickness.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Healthy subjects, aged 18-65, from staff, students and local population of Queen Mary, University of London.

2. Inclusion will be determined on the basis of availability, with no prior selection bias included. They should be able to attend the Wingate Institute for at least 2 x 1 hour sessions.

3. Subjects who score >15 on MSSQ (suggesting that they are sensitive to visually induced nausea).

Exclusion Criteria:

1. Subjects unable to provide informed consent.

2. Subjects with any systemic disease or medications that may influence the autonomic nervous system (e.g. beta-agonists or Parkinson's disease).

3. Subjects who score <15 on MSSQ (suggesting that they are insensitive to visually induced nausea).

4. Pregnant females to prevent any confounding effects on pregnancy related nausea.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Transcutaneous vagal nerve stimulation

Sham vagal nerve stimulation


Locations

Country Name City State
United Kingdom Wingate Institute of Neurogastroenterology London

Sponsors (1)

Lead Sponsor Collaborator
Wingate Institute of Neurogastroenterology

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Farmer AD, Al Omran Y, Aziz Q, Andrews PL. The role of the parasympathetic nervous system in visually induced motion sickness: systematic review and meta-analysis. Exp Brain Res. 2014 Aug;232(8):2665-73. doi: 10.1007/s00221-014-3964-3. Epub 2014 May 4. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction of the subjective sensation of nausea on a visual analogue scale 10 minutes No
Secondary Effect of transcutaneous vagal nerve stimulation on cardiac vagal tone 10 minutes No
Secondary Tolerability of transcutaneous vagal nerve stimulation 10 minutes Yes